Latest Conference Articles

Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.

Patients treated for two years with a combination of glatiramer acetate and estriol experienced a one-third reduction in relapse rate compared with patients who received glatiramer acetate and placebo.

Patients with multiple sclerosis who received thrice-weekly injections of glatiramer acetate 40 mg/ml reported increased satisfaction with their treatment and experienced lower rates of moderate and severe injections site reactions and other adverse events.

Five-year data from the ENDORSE study shows that patients with multiple sclerosis who continued treatment, or who switched from another medication, experienced improved NEDA outcomes.

Mikkel Anthonisan, MD, highlights his experience as the founder of Oceans of Hope, a global voyage to change the perception of multiple sclerosis, at the 2014 Joint ACTRIMS-ECTRIMS Meeting.

Treatment with alemtuzumab was associated with reduced relapse rates and improved MRI outcomes compared to treatment with subcutaneous interferon beta-1a.

Novel drug shown to be more effective than interferon beta-1a in the treatment of multiple sclerosis, but concerns remain over hepatotoxicity, cutaneous reactions, and other adverse events associated with treatment.

A series of nurse-led interventions and patient education, along with titrated drug initiation, were the key components of a successful initiation protocol for patients with multiple sclerosis starting therapy on dimethyl fumarate. The new protocol resulted in fewer discontinuations than the standard initiation protocol.

A version of injectable interferon that multiple sclerosis patients can use far less frequently than existing products is proving safe and effective in clinical trials, its manufacturer says. Biogen Idec announced that new data from the second year of its Phase III clinical trial of peginterferon beta-1a (Plegridy) show it is well tolerated and appears to halt symptoms of relapsing forms of MS. Patients getting the drug had a lower risk of relapse, less disability progression, and fewer new brain lesions than those who got a placebo.

Patients with osteoporosis got some good news at a recent conference when the results of a study showed that taking the drug denosumab can help increase bone density and keep their rate of fractures at a low level.

A new pill could be the next tool in a patient's fight to lose weight, according to a recent study.

Obese and overweight patients who were treated with the drug liraglutide experienced significant weight loss and were less likely to develop type 2 diabetes than patients who received placebo.

A drug which has already been approved for patients with diabetes could have more benefits for people at risk of having heart disease, according a recent study.

A recent study of patients who underwent bariatric surgery showed that even while their weight settled following their procedure their bone loss continued even two years after the operation.

An experimental, first-in-class drug that affects the gut microbiota has been shown to improve glucose tolerance and insulin sensitivity in adults with prediabetes.

A new factor in sleep and sleep apnea among obese and overweight men was introduced by researchers at a recent conference, pointing to the man's testosterone levels as helping determine sleep quality.

Intestinal bacteria levels may be a good marker for determining risk of type 2 diabetes and obesity.

The brains of hyperglycemic patients with Type 1 diabetes produce elevated levels of the neurotransmitter glutamate, which may increase their risk of depression.

Treatment for 12 weeks with empagliflozin led to significant reductions in HbA1c levels and blood pressure compared to placebo.

Phase III trial shows that transplanted purified human pancreatic islets safely restored sustained near-normoglycemia and provided protection from severe hypoglycemia in patients with long-standing type 1 diabetes and iatrogenic hypoglycemia.

Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.

Researchers have identified a previously unrecognized mechanism for SGLT2 inhibitors in the regulation of glucagon and gluconeogenic gene expression.

Patients with type 1 diabetes who had more depressive symptoms measured at baseline and over time appear to be at an increased risk of mortality, even after allowing for likely mediators.

Patients with type 2 diabetes and inadequate glycemic control treated with dapagliflozin plus metformin and sulfonylurea experienced sustained improvements in HbA1c, fasting plasma glucose, weight loss, and systolic blood pressure over 52 weeks.

Patients between the ages of 55 and 80 with type 2 diabetes treated with canagliflozin for more than 100 weeks experienced significant reductions in HbA1C, fasting plasma glucose, bodyweight, and systolic blood pressure.

Study results show long-term treatment with empagliflozin was well tolerated and associated with reductions in HbA1c, bodyweight, and systolic blood pressure compared with placebo and sitagliptin.

Study results presented at ADA 2014 show combination treatment with metformin plus linagliptin delivered consistent HbA1c reductions across different subgroups of patients newly diagnosed with type 2 diabetes, with decreased risk of hypoglycemia.

Study results show that an alternative to currently-marketed injectable agents retains the efficacy of GLP-1 mimetics, while reducing gastrointestinal adverse events and providing the convenience of oral dosing.

Results from the largest population-based, case-control study on the link between incretin therapy and pancreatitis conducted to date indicate that treatment with this class of medications does not confer increased risk of developing pancreatitis.

Combination treatment with insulin degludec and liraglutide was associated with long-term reductions in HbA1c, reduced hypoglycemia risk, and fewer gastrointestinal side effects compared to treatment with the individual medications alone in patients with diabetes.